File Download
  • No File Attached
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Potent antitumor efficacy of XAF1 delivered by conditionally replicative adenovirus vector via caspase-independent apoptosis
  • Basic View
  • Metadata View
  • XML View
TitlePotent antitumor efficacy of XAF1 delivered by conditionally replicative adenovirus vector via caspase-independent apoptosis
 
AuthorsQi, R2 3
Gu, J3
Zhang, Z3
Yang, K3
Li, B3
Fan, J3
Wang, C3
He, Z3
Qiao, L1
Lin, Z2
Liu, XY3 4
 
KeywordsCaspase-independent apoptosis
Gene-virotherapy
XAF1
ZD55
 
Issue Date2007
 
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/cgt
 
CitationCancer Gene Therapy, 2007, v. 14 n. 1, p. 82-90 [How to Cite?]
DOI: http://dx.doi.org/10.1038/sj.cgt.7700992
 
AbstractXAF1 is a newly identified tumor-suppressor gene that can antagonize XIAP and sensitize cells to other cell death triggers. In this study, we utilized ZD55, a conditionally replicative adenovirus (CRAd) similar to ONYX-015 as the vector to transfer XAF1 into the tumor cells to evaluate its antitumor efficacy in vitro and in vivo. Potent and specific cytopathic effect (CPE) was observed upon infection with ZD55-XAF1 in tumor cell lines. Importantly, ZD55-XAF1 exhibited a superior suppression of tumor growth in an animal model of colorectal carcinoma in nude mice compared with Ad-XAF1 (E1-deleted replication-defective viral) and ONYX-015. Complete eradication of the established tumors was observed in four of eight mice. Our data also showed that infection with ZD55-XAF1 resulted in caspase-independent apoptosis. Although caspase-3, poly(ADP-ribose) polymerase were mildly activated in response to ZD55-XAF1 infection, pretreatment with pan-caspase inhibitor hardly influence its apoptosis-inducing activity. In summary, our study strongly suggested that ZD55-XAF1 could serve as an effective gene-virotherapy strategy and has highly potential against human cancers. © 2007 Nature Publishing Group All rights reserved.
 
ISSN0929-1903
2013 Impact Factor: 2.553
2013 SCImago Journal Rankings: 1.064
 
DOIhttp://dx.doi.org/10.1038/sj.cgt.7700992
 
ISI Accession Number IDWOS:000242850400010
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorQi, R
 
dc.contributor.authorGu, J
 
dc.contributor.authorZhang, Z
 
dc.contributor.authorYang, K
 
dc.contributor.authorLi, B
 
dc.contributor.authorFan, J
 
dc.contributor.authorWang, C
 
dc.contributor.authorHe, Z
 
dc.contributor.authorQiao, L
 
dc.contributor.authorLin, Z
 
dc.contributor.authorLiu, XY
 
dc.date.accessioned2010-09-06T07:36:04Z
 
dc.date.available2010-09-06T07:36:04Z
 
dc.date.issued2007
 
dc.description.abstractXAF1 is a newly identified tumor-suppressor gene that can antagonize XIAP and sensitize cells to other cell death triggers. In this study, we utilized ZD55, a conditionally replicative adenovirus (CRAd) similar to ONYX-015 as the vector to transfer XAF1 into the tumor cells to evaluate its antitumor efficacy in vitro and in vivo. Potent and specific cytopathic effect (CPE) was observed upon infection with ZD55-XAF1 in tumor cell lines. Importantly, ZD55-XAF1 exhibited a superior suppression of tumor growth in an animal model of colorectal carcinoma in nude mice compared with Ad-XAF1 (E1-deleted replication-defective viral) and ONYX-015. Complete eradication of the established tumors was observed in four of eight mice. Our data also showed that infection with ZD55-XAF1 resulted in caspase-independent apoptosis. Although caspase-3, poly(ADP-ribose) polymerase were mildly activated in response to ZD55-XAF1 infection, pretreatment with pan-caspase inhibitor hardly influence its apoptosis-inducing activity. In summary, our study strongly suggested that ZD55-XAF1 could serve as an effective gene-virotherapy strategy and has highly potential against human cancers. © 2007 Nature Publishing Group All rights reserved.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationCancer Gene Therapy, 2007, v. 14 n. 1, p. 82-90 [How to Cite?]
DOI: http://dx.doi.org/10.1038/sj.cgt.7700992
 
dc.identifier.citeulike878691
 
dc.identifier.doihttp://dx.doi.org/10.1038/sj.cgt.7700992
 
dc.identifier.epage90
 
dc.identifier.hkuros132102
 
dc.identifier.isiWOS:000242850400010
 
dc.identifier.issn0929-1903
2013 Impact Factor: 2.553
2013 SCImago Journal Rankings: 1.064
 
dc.identifier.issue1
 
dc.identifier.openurl
 
dc.identifier.pmid17008933
 
dc.identifier.scopuseid_2-s2.0-33845619573
 
dc.identifier.spage82
 
dc.identifier.urihttp://hdl.handle.net/10722/77818
 
dc.identifier.volume14
 
dc.languageeng
 
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/cgt
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofCancer Gene Therapy
 
dc.relation.referencesReferences in Scopus
 
dc.subjectCaspase-independent apoptosis
 
dc.subjectGene-virotherapy
 
dc.subjectXAF1
 
dc.subjectZD55
 
dc.titlePotent antitumor efficacy of XAF1 delivered by conditionally replicative adenovirus vector via caspase-independent apoptosis
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Qi, R</contributor.author>
<contributor.author>Gu, J</contributor.author>
<contributor.author>Zhang, Z</contributor.author>
<contributor.author>Yang, K</contributor.author>
<contributor.author>Li, B</contributor.author>
<contributor.author>Fan, J</contributor.author>
<contributor.author>Wang, C</contributor.author>
<contributor.author>He, Z</contributor.author>
<contributor.author>Qiao, L</contributor.author>
<contributor.author>Lin, Z</contributor.author>
<contributor.author>Liu, XY</contributor.author>
<date.accessioned>2010-09-06T07:36:04Z</date.accessioned>
<date.available>2010-09-06T07:36:04Z</date.available>
<date.issued>2007</date.issued>
<identifier.citation>Cancer Gene Therapy, 2007, v. 14 n. 1, p. 82-90</identifier.citation>
<identifier.issn>0929-1903</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/77818</identifier.uri>
<description.abstract>XAF1 is a newly identified tumor-suppressor gene that can antagonize XIAP and sensitize cells to other cell death triggers. In this study, we utilized ZD55, a conditionally replicative adenovirus (CRAd) similar to ONYX-015 as the vector to transfer XAF1 into the tumor cells to evaluate its antitumor efficacy in vitro and in vivo. Potent and specific cytopathic effect (CPE) was observed upon infection with ZD55-XAF1 in tumor cell lines. Importantly, ZD55-XAF1 exhibited a superior suppression of tumor growth in an animal model of colorectal carcinoma in nude mice compared with Ad-XAF1 (E1-deleted replication-defective viral) and ONYX-015. Complete eradication of the established tumors was observed in four of eight mice. Our data also showed that infection with ZD55-XAF1 resulted in caspase-independent apoptosis. Although caspase-3, poly(ADP-ribose) polymerase were mildly activated in response to ZD55-XAF1 infection, pretreatment with pan-caspase inhibitor hardly influence its apoptosis-inducing activity. In summary, our study strongly suggested that ZD55-XAF1 could serve as an effective gene-virotherapy strategy and has highly potential against human cancers. &#169; 2007 Nature Publishing Group All rights reserved.</description.abstract>
<language>eng</language>
<publisher>Nature Publishing Group. The Journal&apos;s web site is located at http://www.nature.com/cgt</publisher>
<relation.ispartof>Cancer Gene Therapy</relation.ispartof>
<subject>Caspase-independent apoptosis</subject>
<subject>Gene-virotherapy</subject>
<subject>XAF1</subject>
<subject>ZD55</subject>
<title>Potent antitumor efficacy of XAF1 delivered by conditionally replicative adenovirus vector via caspase-independent apoptosis</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0929-1903&amp;volume=14&amp;spage=82&amp;epage=90&amp;date=2007&amp;atitle=Potent+antitumor+efficacy+of+XAF1+delivered+by+conditionally+replicative+adenovirus+vector+via+caspase-independent+apoptosis</identifier.openurl>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1038/sj.cgt.7700992</identifier.doi>
<identifier.pmid>17008933</identifier.pmid>
<identifier.scopus>eid_2-s2.0-33845619573</identifier.scopus>
<identifier.hkuros>132102</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-33845619573&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>14</identifier.volume>
<identifier.issue>1</identifier.issue>
<identifier.spage>82</identifier.spage>
<identifier.epage>90</identifier.epage>
<identifier.isi>WOS:000242850400010</identifier.isi>
<publisher.place>United Kingdom</publisher.place>
<identifier.citeulike>878691</identifier.citeulike>
</item>
Author Affiliations
  1. The University of Hong Kong
  2. Shanghai Jiaotong University
  3. Institute of Biochemistry and Cell Biology, Shanghai Institute for Biological Sciences Chinese Academy of Sciences
  4. Zhejiang Sci-Tech University